Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 


Date of Report (Date of earliest event reported): February 27, 2021



(Exact name of registrant as specified in its charter)


Nevada 000-56035 46-2316220
(State or other jurisdiction
of incorporation)
(Commission File Number) (IRS Employer
Identification No.)


1402 El Camino Real

San Clemente, CA

(Address of Principal Executive Offices) (Zip Code)


Registrant's telephone number, including area code (714) 392-9752

(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.


Explanatory Note

     The purpose of this Current Report on Form 8-K/A is to amend the Current Report on Form 8-K filed by Global WholeHealth Partners Corp (the “Company”) on March 2, 2021 (the “Original 8-K”) solely to include the price of $17.50 per dose of ADZ 1222 Covid 19 Vaccine. All other Items contained in the Original 8-K remain unchanged.



Section 8 - Other Events 

Item 8.01 Other Events.


On February 27, 2021, Global WholeHealth Partners Corp (the “Company”) received from Nunzia Pharmaceutical (“Nunvia) the full right as a distributor of Nunzia to sell the ADZ 1222 Covid 19 Vaccine (“Astra-Zeneca vaccine”) by Thameen Healthcare Trading LLC (“Thameen”) with a price of $17.50 per dose . Price is subject to change as Astra-Zeneca vaccine availability may change. The Company will sell and distribute the Astra-Zeneca vaccine in accordance with the guidelines that were given to Nunzia by Thameen who are working with world bodies like the WHO and other Statutory Bodies established for the supply of vaccines, across the world to help in faster inoculation across the world. 

A copy of the letter to sell from Nunzia to the Company and letter to sell from Thameen to Nunzia was furnished as Exhibit 99.1 and Exhibit 99.2 to the Company’s Current Report on Form 8-K filed on March 2, 2021.

Section 9 – Financial Statement and Exhibits
Item 9.01 Financial Statements and Exhibits.

Exhibit No. Document Location
99.1 Letter to sell vaccines from Nunzia Pharmaceutical to Global WholeHealth Partners, Corp., dated February 27, 2021

(Incorporated by reference to Form 8-K filed on March 2, 2021)

99.2 Letter to sell from Thameen Healthcare Trading LLC to Nunzia Pharmaceutical, dated February 26, 2021

(Incorporated by reference to Form 8-K filed on March 2, 2021)






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.







Date: March 8, 2021

By: /s/ Charles Strongo
Charles Strongo

Chief Executive Officer